Animal health company ECO Animal Health Group plc (AIM: EAH) reported on Monday that the European Commission has granted EU marketing authorisation for ECOVAXXIN MS, its poultry vaccine targeting Mycoplasma synoviae. Approval was issued more than a month earlier than expected, following a positive opinion from the Committee for Medicinal Products for Veterinary Use in November 2025.

ECOVAXXIN MS provides active immunisation for future layer and breeder chickens from four weeks of age, reducing air-sac and foot-pad lesions and limiting egg production losses linked to Mycoplasma synoviae infections. Infection is associated with material economic impact in laying hens, where egg output can fall by 5–10%.

The company stated that a further market update will be provided in early 2026 outlining plans for the EU commercial launch of ECOVAXXIN MS.

ECO Animal Health Group plc operates globally in animal health, developing and marketing branded veterinary pharmaceuticals, with a focus on antibiotics and vaccines for pigs and poultry. The group holds marketing authorisations in more than 70 countries, employs over 200 staff worldwide and is headquartered in the UK, with integrated R&D and manufacturing operations.